Please assess the completion status of the following clinical trial:

Trial Title: BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a diagnosis of OAG or OHT in 1 or both eyes.~* Subjects who are treatment-naïve must meet the following IOP requirements at Visit 1 (Screening), and pretreated subjects must meet the following IOP requirements at Visit 2 (Washout): Intraocular pressure ≥ 22 mmHg in at least 1 eye and ≤ 36 mmHg in both eyes.~Exclusion Criteria:~* Subjects who have been exposed to BOL-303259-X within 3 months prior to Visit 1 (Screening).~* Subjects with a history or presence of chronic generalized systemic disease that the Investigator feels might increase the risk to the subject or confound the results of the study.~* Subjects with an irregular daily sleep schedule.~* Subjects who are unable to wear sleep monitoring device for 7 days prior to laboratory study.~* Subjects with an anticipated need to initiate or modify medication (systemic or topical) that is known to affect IOP.~* Subjects for whom concomitant use of medications may interact with the safety or efficacy of a nitric oxide.~* Subjects with known hypersensitivity or contraindications to latanoprost or any of the ingredients in the study drugs.~* Subjects who are expected to require treatment with ocular or systemic corticosteroids.~* Subjects who are in need of any other topical or systemic treatment of OAG or OHT.~* Subjects who are unable to discontinue contact lens use during and for 24 hours before the laboratory study.~* Subjects with a central corneal thickness greater than 600 μm in either eye.~* Subjects with any condition that prevents reliable applanationtonometry in either eye.~* Subjects with advanced glaucoma and subjects with a cup/disc ratio greater than 0.8 or a history of split fixation, or a field loss threatening fixation in either eye.~* Subjects with previous or active corneal disease.~* Subjects with a history of severe dry eye.~* Subjects with active optic disc hemorrhage.~* Subjects with a history of central/branch retinal vein or artery occlusion.~* Subjects with a history of macular edema.~* Subjects with very narrow angles and subjects with angle closure, congenital, and secondary glaucoma, and subjects with history of angle closure in either eye.~* Subjects with a diagnosis of a clinically significant or progressive retinal disease in either eye.~* Subjects with any intraocular infection or inflammation within 3 months prior to Visit 1 (Screening).~* Subjects with a history of ocular laser surgery within the 3 months prior to Visit 1 (Screening).~* Subjects with a history of incisional ocular surgery or severe trauma within 3 months prior to Visit 1 (Screening).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Timolol Maleate (Type: ACTIVE_COMPARATOR): Timolol maleate ophthalmic solution 0.5% administered 1 drop BID once in morning and once in the evening for 4 weeks.
- BOL-303259-X (Type: EXPERIMENTAL): BOL-303259-X topical ophthalmic solution administered 1 drop QD in the evening for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).